Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MME | P08473 | 2/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | LAP3 | P28838 | 3/20 | 0.46 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.45 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.45 |
| ▸ | GRN | P28799 | 1/20 | 0.45 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7361688 | 0.90 | ALDH1A1 (0.51) | ALDH1A1MEN1LMNAKMT2AMME | |
| SCHEMBL10592046 | 0.90 | ALDH1A1 (0.51) | ALDH1A1MEN1LMNAKMT2AMME | |
| SCHEMBL29648540 | 0.86 | BIRC2 (0.52) | MMEFOLH1TSHR | |
| SCHEMBL6264659 | 0.84 | FOLH1 (0.64) | ALDH1A1MEN1LMNAKMT2AMME | |
| SCHEMBL4572561 | 0.84 | FOLH1 (0.64) | ALDH1A1MEN1LMNAKMT2AMME | |
| SCHEMBL29530212 | 0.82 | TGFBR1 (0.55) | ALDH1A1LMNAMMETSHR | |
| SCHEMBL15623775 | 0.82 | ALDH1A1 (0.62) | ALDH1A1MEN1LMNAKMT2AMME | |
| SCHEMBL9837855 | 0.81 | KDM4E (0.53) | ALDH1A1LMNAMMEFOLH1MAPT | |
| SCHEMBL4027352 | 0.80 | PLA2G2A (0.61) | ALDH1A1MEN1LMNAKMT2AMME | |
| SCHEMBL6256944 | 0.80 | ALDH1A1 (0.60) | ALDH1A1MEN1LMNAKMT2AMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250387350-A1 | BIOMARKERS OF METAP2 INHIBITORS AND APPLICATIONS THEREOF | SYNDEVRX INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12419846-B2 | Biomarkers of METAP2 inhibitors and applications thereof | SYNDEVRX, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| EP-4589059-A2 | PROCESS FOR MICROSATELLITE INSTABILITY DETECTION | Personal Genome Diagnostics, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| EP-3717520-B1 | PROCESS FOR MICROSATELLITE INSTABILITY DETECTION | PERSONAL GENOME DIAGNOSTICS INC (US) | 2025-04-16 | — | — | EP | disclosed |
| US-20230404963-A1 | COMBINATIONS OF METAP2 INHIBITORS AND CD4/6 INHIBITORS FOR THE TREATMENT OF CANCER | SYNDEVRX, INC. | 2023-12-21 | — | — | US | disclosed |
| EP-4243807-A1 | COMBINATIONS OF METAP2 INHIBITORS AND CDK4/6 INHIBITORS FOR THE TREATMENT OF CANCER | Syndevrx, Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| US-20230225996-A1 | BIOMARKERS OF METAP2 INHIBITORS AND APPLICATIONS THEREOF | SYNDEVRX, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230160002-A1 | Process for Microsatellite Instability Detection | Personal Genome Diagnostics Inc. (US) | 2023-05-25 | — | — | US | disclosed |
| US-11612577-B2 | Biomarkers of METAP2 inhibitors and applications thereof | SYNDEVRX, INC. (US) | 2023-03-28 | — | — | US | disclosed |
| US-11597967-B2 | Process for microsatellite instability detection | Personal Genome Diagnostics Inc. (US) | 2023-03-07 | — | — | US | disclosed |
| US-20220389449-A1 | COMPOSITIONS FOR THE TREATMENT OF DISEASE | VOYAGER THERAPEUTICS, INC. | 2022-12-08 | — | — | US | disclosed |
| WO-2022103834-A1 | COMBINATIONS OF METAP2 INHIBITORS AND CDK4/6 INHIBITORS FOR THE TREATMENT OF CANCER | SYNDEVRX, INC. (US) | 2022-05-19 | — | — | WO | disclosed |
| US-11326182-B2 | Compositions for the treatment of disease | VOYAGER THERAPEUTICS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230404963-A1 | COMBINATIONS OF METAP2 INHIBITORS AND CD4/6 INHIBITORS FOR THE TREATMENT OF CANCER | CDK6, MPHOSPH6, CD4 | ALDH1A1 4609/4885MEN1 1171/4885LMNA 3836/4885 |
| US-20250387350-A1 | BIOMARKERS OF METAP2 INHIBITORS AND APPLICATIONS THEREOF | METAP2, TGFB2, IGF2BP2 | ALDH1A1 4262/4885MEN1 3094/4885LMNA 4027/4885 |
| US-20230225996-A1 | BIOMARKERS OF METAP2 INHIBITORS AND APPLICATIONS THEREOF | METAP2, METAP1, PEBP1 | ALDH1A1 3316/4885MEN1 984/4885LMNA 3649/4885 |
| US-11612577-B2 | Biomarkers of METAP2 inhibitors and applications thereof | METAP2, METAP1, PCK2 | ALDH1A1 3227/4885MEN1 1115/4885LMNA 3634/4885 |
| US-12419846-B2 | Biomarkers of METAP2 inhibitors and applications thereof | METAP2, METAP1, PEBP1 | ALDH1A1 3316/4885MEN1 984/4885LMNA 3649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.